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Hutchinson–Gilford Progeria Syndrome with G608G LMNA 
Mutation
Hutchinson–Gilford progeria syndrome (HGPS) is a rare condition originally described by 
Hutchinson in 1886. Death result from cardiac complications in the majority of cases and 
usually occurs at average age of thirteen years. A 4-yr old boy had typical clinical findings 
such as short stature, craniofacial disproportion, alopecia, prominent scalp veins and 
sclerodermatous skin. This abnormal appearance began at age of 1 yr. On serological and 
hormonal evaluation, all values are within normal range. He was neurologically intact with 
motor and mental development. An echocardiogram showed calcification of aortic and 
mitral valves. Hypertrophy of internal layer at internal carotid artery suggesting 
atherosclerosis was found by carotid doppler sonography. He is on low dose aspirin to 
prevent thromboembolic episodes and on regular follow up. Gene study showed typical 
G608G (GGC- > GGT) point mutation at exon 11 in LMNA gene. This is a rare case of 
Hutchinson-Gilford progeria syndrome confirmed by genetic analysis in Korea.
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CASE REPORT
Pediatrics
INTRODUCTION
Progeria is a genetic disorder rarely encountered and is charac­
terized by features of premature aging. It is also known as “Hut­
chin  son­Gilford Progeria syndrome” (1). Although signs and 
symptoms vary in age of onset and severity, they are remark­
ably consistent overall. Children with HGPS usually appear nor­
mal at birth. Profound failure to thrive occurs during the first 
year (2). Characteristic facies, with receding mandible, narrow 
nasal bridge and pointed nasal tip develop. Motor and mental 
development is normal. Death occurs as a result of complications 
of severe atherosclerosis, either cardiac disease (myocardial in­
farction) or cerebrovascular disease (stroke), generally between 
ages 6 and 20 yr. Average life span is approximately 13 yr (2). 
  We report here a 4­yr­old boy with an apparently typical Hut­
chinson–Gilford progeria syndrome with G608G LMNA muta­
tion. 
CASE DESCRIPTION
A 4­yr­old boy was referred to the department of pediatrics with 
short stature and sclerodermatous skin on 2 September 2010. 
He was the first child born to non­consanguinous parents with 
no significant family history. He was born at full term with birth 
weight of 3.35 kg by spontaneous virginal delivery. His abnormal 
appearance was not found at birth. At age of 1 yr, growth retar­
dation, hair loss, and alteration of skin color on the abdominal 
region began.
  On physical examination, his length was 88 cm and weight 
11.5 kg, both less than 3rd percentile and head circumference 
was 52 cm (ca. 77th percentile) (Fig. 1). He had generalized in­
durated and shiny skin associated with decreased subcutane­
ous fat, especially on the abdomen. His hair was fine and sparse 
and his scalp veins were easily visible (Fig. 1). His anterior fon­
tanelle was still patent (horizontal diameter 1.7 cm, vertical di­
ameter 1.4 cm). He had craniofacial disproportion for his age 
due to micrognatia, prominent eyes, scant eyelashes and small 
nose. His bone age was 3 yr. He was neurologically intact with 
motor and mental development. On serological and hormonal 
evaluation, all values are within normal range. An echocardio­
gram did not show concentric left ventricular hypertrophy nor 
increased left ventricular pressure but showed calcification of 
aortic and mitral valves (Fig. 2). Hypertrophy of internal layer at 
internal carotid artery suggesting atherosclerosis was found by 
carotid doppler sonography (Fig. 2). He is on low dose aspirin 
to prevent thromboembolic episodes and on regular follow up.
  We obtained his DNA from white blood cell in peripheral blood 
and sequencing was performed by such method as belows; Sam­
ples were extracted using a MG
TM Tissue Kit. We designed poly­
merase chain reaction (PCR) primers using the Primer 3 pro­
gram. The primers Tms ranged between 59°C and 62°C as far as 
possible. The PCR reaction was performed with 20 ng of genom­Kim HK, et al.  •  Hutchinson–Gilford Progeria Syndrome with G608G LMNA Mutation
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ic DNA as the template in a 30 µL reaction mixture by using a 
EF­Taq (SolGent, Korea) as follows: activation of Taq polymerase 
at 95°C for 2 min, 35 cycles of 95°C for 1 min, 55°C­63°C, and 72°C 
for 1 min each were performed, finishing with a 10 min step at 
72°C. The amplification products were purified with a multi­
screen filter plate (Millipore Corp., Bedford, MA, USA). Sequenc­
A B
Fig. 1. (A) General appearance of the patient with characteristic pre-
maturely aged appearance, retarded growth. (B) Lateral and top view 
of the head showing macrocephaly, alopecia, prominent scalp veins.
Fig. 2. (A) Echocardiographic parasternal long-axis view showes mitral annulus 
and mitral valve calcification compatible with senile process. (B) Echocardiograph-
ic parasternal short-axis view of arotic valve showes inhomogeneously increased 
echodensity of the valve and thickening of the leaflets. (C) Echocardiographic view 
of left commom carotid artery shows that the wall is thicker than the mean chron-
ological age’s.  C
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ing reaction was performed using a PRISM BigDye Terminator 
v3.1 Cycle sequencing Kit. The DNA samples containing the ex­
tension products were added to Hi­Di formamide (Applied Bio­
systems, Foster City, CA). The mixture was incubated at 95°C 
for 5 min, followed by 5 min on ice and then analyzed by ABI 
Prism 3730XL DNA analyzer (Applied Biosystems, Foster City, 
CA, USA). The results were analyzed using the software DNA­
star (http://www.dnastar.com).
  Gene study showed typical G608G (GGC­ > GGT) point mu­
tation at exon 11 in LMNA gene (Fig. 3). He had a younger sister 
with normal appearance. we planned to carry out gene study 
for her and his family but couldn’t for their refusal. After the di­
agnosis, he regularly visits our clinic for routine lab., echocardio­
gram and carotid doppler sonography. In addition, with our help, 
he was enrolled in The Progeria Research Foundation (PRF) in 
USA and is waiting for farnesyltransferase inhibitors (FTIs) for 
clinical trials. 
DISCUSSION
Progeria was described for the first time in 1886, by Hutchinson, 
and ratified by Gilford, in 1904. It occurs sporadically, with an 
incidence of 1 in 8 million live births and there are approximate­
ly 150 cases described in the medical literature. It predominates 
in males with a ratio of 1.5:1 and greater susceptibility of Cauca­
sians can be seen in 97% of cases (3). In Korea, 5 cases were re­
ported in the medical literature (4­9). This is the first case diag­
nosed as Hutchinson­Gilford Progeria syndrome by gene study 
in Korea.
  Children with HGPS look so similar that they could all be mis­
taken for siblings. There is variability in onset and rate of pro­
gression of disease among children, although the final pheno­
type in these patients is remarkably similar, underscoring the 
identical common mutation that leads downstream to similar 
pathobiology (10). In this syndrome, the rate of aging is acceler­
ated up to seven times that of normal. The average life span is 
13 yr (range 7­27 yr), but occasionally can survive till the age of 
45 yr. The death is mainly due to cardiovascular complications 
like myocardial infarction or congestive heart failure. The evi­
dence supports the de novo point mutations in lamin A (LMNA) 
gene as the causative factor has been increasing (11).
  The most common HGPS­associated mutation, Gly608Gly, 
causes 150 nucleotides encoded in exon 11 to be spliced out of 
the final mRNA and results in a protein that lacks 50 amino ac­
ids. This protein, progerin, retains its C­terminal CAAX motif 
but lacks sequences that are required for complete processing 
and is, therefore, stably farnesylated (12). Lamin A is a protein 
meshwork lining the nucleoplasmic face of the inner nuclear 
membrane and represents an important determinant of inter­
phase nuclear architecture (13). Progerin apparently acts in a 
dominant­negative manner on the nuclear function of cell types 
that express Lamin A (14). The increased progerin causes nu­
clear blebbing and altered shape of the nucleus.
  The clinical manifestations are divided into major criteria and 
signs usually presents itself as follows: the major criteria are a 
bird­like face (which occurs around 6 months to one year of age), 
alopecia, prominent veins on the scalp, big eyes, micrognathia, 
abnormal and slow dentition, pear­shaped chest, short clavi­
cles, bow legs (coxa valga), short upper limbs and prominent 
articulations, low stature and weight with normal bone age, in­
complete sexual maturation, reduction of the adipose tissue and 
adequate psycho­motor development with normal intelligence. 
Diagnosis is essentially clinical with major criteria appearing 
during the first and second years of life (15). Cutaneous mani­
festations are earlier to appear followed by skeletal and cardio­
vascular systems. In our case, cardiovascular systems showed 
calcification of aortic and mitral valves and hypertrophy of in­
ternal layer at internal carotid artery suggesting atherosclerosis. 
Skeletal abnormalities include osteolysis, osteoporosis, dystro­
phic clavicles, coxa valga, “horse riding” stance, thinning of cra­
nial bones, delayed closure of cranial sutures and anterior fon­
tanelle. 
  Prognosis is detrimental to the health of the patient and life 
expectancy is around 13 yr. The main mortality factors are car­
diovascular diseases (75%) like acute myocardial infarction. De­
spite the advances in cardiovascular surgery, the low survival 
rate remains due to the high capacity of the disease to reproduce 
the erythematous plaques. Low­dose aspirin is recommended 
as prophylaxis to prevent atherosclerotic changes (15).
  A vigorous research effort in the pharmaceutical industry has 
identified and developed a number of small­molecule com­
pounds that potently and selectively inhibit farnesyltransferase 
(FTase). In vitro studies in mice suggest a possible role for the use 
of farnesyltransferase inhibitors (FTIs) in progeria (15). Farne­
sylation, a posttranslational modification involving the addition 
of a 15­carbon isoprene moiety, was implicated as a potential 
Fig. 3. Sequence analysis of exon 11 of LMNA gene. This 
result shows G608G (GGC->GGT) heterogenous substi-
tution in LMNA gene. Kim HK, et al.  •  Hutchinson–Gilford Progeria Syndrome with G608G LMNA Mutation
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anticancer target when it was discovered that the oncoprotein 
Ras, which has been estimated to be involved in up to 30% of all 
human cancers, required farnesylation for its function. Two of 
these drugs (lonafarnib_SCH66336 from Schering­Plough, Ke­
nilworth, NJ, and tipifarnib_R115777 from Johnson & Johnson, 
New Brunswick, NJ) have entered phase III trials and have been 
well tolerated, including in trials involving children (16). Lona­
farnib competes with protein substrates for binding to the FTase 
enzyme (17). Similar to Ras, the Lamin A precursor is also farne­
sylated, with farnesylation serving as a required step to insert 
prelamin A into the nuclear membrane as well as to allow for 
the two downstream cleavage steps which complete the pro­
cessing of Lamin A (18). For this patient, we are waiting for FTIs 
for clinical trials.
  With the knowledge that the single C­to­T base change seen 
in nearly all cases of HGPS created a cryptic splice site and, thus, 
deleted the normal second endoproteolytic cleavage site in the 
Lamin A processing pathway, it was hypothesized that progerin 
was forced to retain its farnesyl group and, therefore, could not 
dissociate itself from the nuclear membrane. With other mem­
bers of the nuclear lamina also potentially becoming trapped in 
complexes with the mislocalized progerin, a mechanistic con­
nection between this permanently farnesylated state and the 
striking nuclear blebbing and disrupted nuclear architecture 
seen in HGPS cells was proposed, and the possibility of prevent­
ing or reversing this phenotype through FTIs was raised. Detailed 
study of HGPS and LMNA mutations may also advance our un­
derstanding of the process of aging. Why do LMNA mutant cells 
enter senescence earlier than normal cells? (19).
  In summary, we found a new patient with typical Hutchin­
son­Gilford Progeria syndrome with mutation of the G608G in 
the LMNA gene. This is the first case diagnosed as Hutchinson­
Gilford Progeria syndrome by gene study in Korea.
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